drugset
drugset / Trial / NCT02554942

A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors

NCT02554942 ↗

Phase 4 Completed 28 enrolled Hoffmann-La Roche
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety of subcutaneous (SC) epoetin beta (NeoRecormon) in adults with solid tumors being treated with platinum-based chemotherapy capable of inducing anemia. The anticipated time on study treatment is 16 weeks, and the target sample size is approximately 208 individuals.

Timeline

Start
2004-06
Primary completion
2005-09
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 450 iu/kg Subcutaneous

Indications

anemia